Powered by LumidaWealth.com
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
No Result
View All Result
  • Lumida Wealth
  • Lumida Ledger
  • LUMIDA ETF
  • About Us
Home News

Novo Nordisk Stock Dips as Eli Lilly’s Mounjaro Outshines Wegovy in Weight Loss

by Team Lumida
July 9, 2024
in News
Reading Time: 3 mins read
A A
0
Novo Nordisk Stock Dips as Eli Lilly’s Mounjaro Outshines Wegovy in Weight Loss

"Two Boxes of Ozempic (Semagalutide) / Wegovy Pens - 0.25mg and 0.5mg" by chemist4u is licensed under CC BY 2.0

Share on TelegramShare on TwitterShare on FacebookShare on LinkedinShare on Whatsapp

Key Takeaways

  1. Novo Nordisk shares drop 1.1% after study favors Eli Lilly’s Mounjaro.
  2. Mounjaro users 76% more likely to lose 5% body weight than Ozempic users.
  3. Weight-loss drug market could hit $150 billion annually by early 2030s.

What Happened?

Novo Nordisk shares fell 1.1% on Tuesday following a JAMA Internal Medicine analysis showing Eli Lilly’s Mounjaro leads to faster and more significant weight loss compared to Novo’s Ozempic. The study examined health records and pharmacy data for 9,193 patients on Mounjaro and a similar number on Ozempic.

Results indicated Mounjaro users were 76% more likely to lose at least 5% of their body weight, twice as likely to lose 10%, and three times as likely to lose 15%. The average participant weighed 242 pounds, and about half had type 2 diabetes.

Why It Matters?

For investors, this data is crucial. The weight-loss drug market is booming and could be worth $150 billion annually by the early 2030s. Novo Nordisk and Eli Lilly are key players, historically dominating the insulin market. However, this study shifts the competitive landscape.

Novo Nordisk noted that the analysis did not include its Wegovy drug, emphasizing the need for head-to-head clinical trials for an accurate comparison. Eli Lilly’s Mounjaro showing better results could influence market share and profitability.

What’s Next?

Investors should monitor upcoming clinical trials comparing these weight-loss drugs directly. Novo Nordisk aims to bolster its market position by emphasizing Wegovy’s effectiveness. Meanwhile, Eli Lilly will likely continue capitalizing on Mounjaro’s superior results.

The competition will likely intensify as both companies race to scale up production to meet the soaring demand. Keep an eye on future regulatory approvals, market expansions, and any new data that could sway market dynamics further.

Source: Investing.com
Tags: Eli LillyMounjaroNovo NordiskOzempicweight-loss drugs
Previous Post

Could Trump’s Second Term Boost Your Portfolio?

Next Post

Fed’s Rule Tweak Could Save Big Banks Billions – What You Need to Know

Recommended For You

Costco’s US Comparable Sales May Grow More Than 10% in November as Tech Outages Spark Emergency Stockpiling, Mizuho Says, Raising Its Target to $1,150

by Team Lumida
15 hours ago

Mizuho said tech outages are driving panic buying at Costco, estimating late-October US comps ex-gas rose 11% to 12%, and lifted its target to $1,150.

Read more

Textron Sells Its Industrial Segment to Kingswood Capital for $1.2 Billion and Authorizes a 35 Million-Share Buyback to Focus on Aviation, Bell and Defense

by Team Lumida
15 hours ago

Textron agreed to sell its industrial unit for $1.2 billion, expects about $1.1 billion in net proceeds, and approved a new 35 million-share buyback.

Read more

Apple Trades at 37 Times Forward Earnings, Its Highest Since 2007, After a 30% Gain Makes It the Market’s AI Haven and a $5.1 Trillion Company

by Team Lumida
15 hours ago

Apple’s 30% gain this year has pushed it to 37 times forward earnings and a record PEG ratio, as investors pay up for a stock seen as an...

Read more

Bitcoin Erases Its Bessent Rally Near $64,000 as Perpetual Futures Open Interest Falls to $41.6 Billion, the Lowest Since November 2024, and Citi Cuts Its Targets

by Team Lumida
15 hours ago

Bitcoin wiped out its late-summer rally as leverage and liquidity faded, ETF outflows hit $2.6 billion this month, and Citi trimmed its BTC and ETH targets.

Read more

MARA Prices $185 Million of 8.75% Debt to Help Fund Its $1.5 Billion Ohio Power Plant Deal, a Week After Selling $1.1 Billion of Bitcoin to Repay Loans

by Team Lumida
15 hours ago

MARA priced $185 million of 8.75% bonds tied to its Long Ridge power plant purchase, and its shares rose about 4.7% premarket.

Read more

Pending Home Sales Fall 4.7% to the Lowest in the Index’s 25-Year History, as Single-Family Permits Drop 8.7% to a May 2020 Low and Mortgage Applications Slip 2.3%

by Team Lumida
15 hours ago

Pending home sales hit a record low in October, single-family permits fell 8.7%, and mortgage applications dropped as rates rose to 7.35%.

Read more

TJX Raises Its Full-Year EPS Outlook to $5.17-$5.20 After Comparable Sales Rise 4% and Sales Hit $16 Billion, Sending Shares Up 6.6% Premarket

by Team Lumida
15 hours ago

TJX raised its full-year profit outlook after Q3 sales rose 6% to $16 billion and comparable sales beat at 4%, sending the stock up 6.6% premarket.

Read more

Lowe’s Raises Its Sales Outlook to About $92.5 Billion as Online Sales Jump 17.4% and Comparable Sales Rise 1.8%, Yet Shares Slip More Than 3% Premarket

by Team Lumida
15 hours ago

Lowe’s lifted its full-year sales outlook to about $92.5 billion on 17.4% online growth and pro strength, though shares fell more than 3% premarket.

Read more

Jensen Huang and Commerce Secretary Lutnick Agree to Appear Before the Senate Banking Committee, as House Democrats Probe Cantor Fitzgerald’s Nvidia Holdings

by Team Lumida
15 hours ago

Tim Scott said Huang and Lutnick agreed to appear before Christmas, as House Democrats sought records on Cantor Fitzgerald’s Nvidia stake.

Read more

Dow Drops 426 Points as Nvidia’s Post-Earnings Bounce Fizzles, With CoreWeave Down 6%, Nebius 4% and Iren 3% as Neoclouds Reverse Early Gains

by Team Lumida
15 hours ago

The Dow fell 426 points as Nvidia gave up its post-earnings gains, while CoreWeave, Nebius and Iren reversed early premarket jumps.

Read more
Next Post
bank, money, finance

Fed’s Rule Tweak Could Save Big Banks Billions – What You Need to Know

red and black metal tower during sunset

The World's Largest Oil Company Believes Petrol Engines Will Outlast Electric Cars

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Related News

high rise buildings during daytime

Commercial Real Estate Risks Trigger Potential Downgrades for These US Banks

June 10, 2024
Bitcoin Could Drop to $50K Before a Potential Fed-Driven Rally

SEC Draws the Line on Crypto, Ending Years of Regulatory Ambiguity

March 18, 2026
low angle photography of high rise building under cloudy sky

Why Global Insurers Are Diving into Private Credit Despite Risks

June 7, 2024

Subscribe to Lumida Ledger

Browse by Category

  • Lifestyle
    • Family Office
    • Health and Longevity
    • Legacy
    • Next Gen Wealth
    • Trust, Tax, and Estate
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Latest
    • Macro
    • Markets
    • Real Estate
  • Opinions
    • Investing Philosophy
    • Op-Ed
  • Research
    • Trackers
  • Themes
    • Aging & Longevity
    • AI
    • Biotech
    • CRE
    • Cybersecurity
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
    • Software
Facebook Twitter Instagram Youtube TikTok LinkedIn
Lumida News

Premium insights to help you invest beyond the ordinary. Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser

CATEGORIES

  • Aging & Longevity
  • AI
  • Alt Assets
  • Biotech
  • CRE
  • Crypto
  • Cybersecurity
  • Digital Assets
  • Equities
  • Family Office
  • Health and Longevity
  • Investing Philosophy
  • Latest
  • Legacy
  • Legacy Brands
  • Lifestyle
  • Macro
  • Markets
  • News
  • Next Gen Wealth
  • Nuclear Renaissance
  • Op-Ed
  • Private Credit
  • Real Estate
  • Software
  • Themes
  • Trackers
  • Trust, Tax, and Estate

BROWSE BY TAG

AI AI chips Amazon Apple Artificial Intelligence Banking Bank of America China Commercial Real Estate CPI data centers Donald Trump EARNINGS ELON MUSK Federal Reserve financial services generative AI Goldman Sachs Google India Inflation Interest Rates Investment Strategy Japan Jerome Powell JPMorgan Markets Meta Microsoft Nasdaq Novo Nordisk Nuclear Energy Nvidia oil OpenAI private equity S&P 500 SEC Semiconductor stock market stock surge Tech Stocks tesla Trump Whale Watch

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018

No Result
View All Result
  • Home
  • Earnings
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018